S-1: Aspire Biopharma Holdings Registers Resale of Up to 3.15 Million Shares After Business Combination

Aspire Biopharma Holdings files for the resale of up to 3.15 million shares of common stock following its business combination, including shares issued as commitment shares and those reserved for conversion of convertible debentures.

Summary

• Aspire Biopharma Holdings, Inc. is registering the resale of up to 3,150,554 shares of its common stock.
• This includes 2,213,054 shares previously issued to selling shareholders as commitment shares and 937,500 shares reserved for issuance upon conversion of convertible debentures.
• The registration is required by a registration rights agreement with Cobra Alternative Capital Strategies, LLC, Target Capital X LLC, and a purchase agreement with Arena Business Solutions Global SPC II, Ltd.
• Aspire will not receive any proceeds from the sale of these shares by the selling shareholders.
• The company will bear all costs associated with the registration, while the selling shareholders will cover commissions and discounts related to their sales.
• Trading of Aspire's common stock and warrants began on the Nasdaq Global Market on February 20, 2025, under the symbols ASBP and ASBPW, respectively.
• On April 7, 2025, the closing sale price of Aspire's common stock was $0.4012 per share, and the closing price of its warrants was $0.0441 per warrant.

Sentiment

Score: 5

Explanation: The document is primarily factual, outlining the registration of shares for resale. The sentiment is neutral as it mainly describes the mechanics of the offering and related agreements.

Risks

• Investing in shares of our common stock or warrants involves risks that are described in the Risk Factors section beginning on page 19 of this prospectus.

Future Outlook

The document outlines the company's plans to develop and commercialize sublingual delivery technologies, particularly for aspirin, and to seek FDA approval for its products.

Industry Context

The announcement reflects Aspire Biopharma's transition into a publicly traded entity following its business combination, positioning it to pursue its biopharmaceutical development plans in a competitive industry landscape.

Stakeholder Impact

• Shareholders may experience dilution due to the potential conversion of debentures and the issuance of shares under the ELOC agreement.
• The resale of shares by selling shareholders could influence the market price of the stock.

Next Steps

• The Selling Shareholders may offer and sell any or all of the shares of common stock and warrants set forth below pursuant to this prospectus and any accompanying prospectus supplement.
• Aspire plans to conduct an in vivo single-dose bioavailability study in healthy human volunteers in approximately April 2025 (Trial 1).
• Following completion of Trial 1, Aspire plans to request a pre-IND meeting with the FDA in the second quarter of 2025 to discuss plans for continued development of the high dose aspirin leading to submission of a section 505(b)(2) NDA.

Key Dates

Keywords

resale, common stock, Aspire Biopharma, registration, shares, warrants, debentures, commitment shares, business combination, ASBP, ASBPW